Cancer News and Research

Latest Cancer News and Research

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Seminar focuses on approaches to improve small molecule discovery programs

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, last week held the latest seminar in its "Innovation for Experimentation" series.

23 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

Report: Quality of care for insured Americans slipped in 2008

CNNMoney reports that for the first time in more than 10 years, the "overall quality of health care" for Americans insured through commercial and public plans appears to have slipped.

23 Oct 2009

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

The American Jewish Committee urged the Egyptian government to allow a team of Israeli breast cancer researchers to enter the country for a major conference sponsored by Susan G. Komen for the Cure, a leading breast cancer awareness group based in the U.S. The Israeli team was denied entry into Egypt earlier this week, despite having previously received the necessary clearances to attend the conference in Alexandria.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

NCI awards $2.8 million grant to Allegro Diagnostics

Allegro Diagnostics, a leader in the field of molecular diagnostics for lung cancer, has announced that its clinical study for BronchoGen(TM), a diagnostic test for patients suspected of having lung cancer, will receive up to $2.8 million in funding for a Phase I/II Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

22 Oct 2009

Phase Forward releases IRT 5.0 Interactive Response Technology solution

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a major new release of its Interactive Response Technology (IRT) solution, Phase Forward™ IRT 5.0.

22 Oct 2009

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010.

22 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

FMWC partners with SOGC and SCC to launch Pap test campaign

The Federation of Medical Women of Canada (FMWC) has joined forces with the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Society of Canadian Colposcopists (SCC) to launch this year's Pap test campaign during Cervical Cancer Awareness Week. Together, we hope to increase the scope, reach and impact of the campaign. With this collaborative effort, we aim to provide more Pap tests and deal with abnormal results in a more expeditious manner.

22 Oct 2009

Applied Biosystems announces the global availability of its 3500 Series Genetic Analyzer

Applied Biosystems, part of Life Technologies Corporation, today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems’ industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use.

22 Oct 2009

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

NCI implements NanoString Technologies' nCounter Analysis System

NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that the National Cancer Institute (NCI) is employing its nCounter™ Analysis System at two of its core labs.

From NanoString Technologies 22 Oct 2009

Cancer News and Research

Latest Cancer News and Research

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Seminar focuses on approaches to improve small molecule discovery programs

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

Aethlon Medical establishes ESI as a wholly owned subsidiary

Report: Quality of care for insured Americans slipped in 2008

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

Early diagnostic for ovarian cancer to be developed

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

NCI awards $2.8 million grant to Allegro Diagnostics

Phase Forward releases IRT 5.0 Interactive Response Technology solution

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

KemPharm commences KP106 Phase 1 clinical trial for ADHD

FMWC partners with SOGC and SCC to launch Pap test campaign

Applied Biosystems announces the global availability of its 3500 Series Genetic Analyzer

Rosetta Genomics, GTG sign exclusive distribution agreement

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

Merck's sales increases by 2% in third quarter 2009

NCI implements NanoString Technologies' nCounter Analysis System

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in